Mirtazapine in essential tremor: A double‐blind, placebo‐controlled pilot study
Identifieur interne : 004039 ( Main/Exploration ); précédent : 004038; suivant : 004040Mirtazapine in essential tremor: A double‐blind, placebo‐controlled pilot study
Auteurs : Rajesh Pahwa [États-Unis] ; Kelly E. Lyons [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2003-05.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Aged, Antagonist, Antidepressive Agents, Tricyclic (administration & dosage), Antidepressive Agents, Tricyclic (pharmacology), Antidepressive Agents, Tricyclic (therapeutic use), Chemotherapy, Cross-Over Studies, Double blind study, Double-Blind Method, Essential, Essential Tremor (diagnosis), Essential Tremor (drug therapy), Female, Human, Humans, Male, Mianserin (administration & dosage), Mianserin (analogs & derivatives), Mianserin (pharmacology), Mianserin (therapeutic use), Mirtazapine, Outcome Assessment (Health Care), Placebo, Psychomotor Performance (drug effects), Questionnaires, Severity of Illness Index, Treatment, Tremor, double‐blind, mirtazapine, placebo, tremor, α2-Adrenergic receptor.
- MESH :
- chemical , administration & dosage : Antidepressive Agents, Tricyclic, Mianserin.
- chemical , analogs & derivatives : Mianserin.
- chemical , pharmacology : Antidepressive Agents, Tricyclic, Mianserin.
- chemical , therapeutic use : Antidepressive Agents, Tricyclic, Mianserin.
- diagnosis : Essential Tremor.
- drug effects : Psychomotor Performance.
- drug therapy : Essential Tremor.
- Aged, Cross-Over Studies, Double-Blind Method, Female, Humans, Male, Outcome Assessment (Health Care), Questionnaires, Severity of Illness Index.
Abstract
We sought to determine whether mirtazapine is safe and well‐tolerated as a treatment for essential tremor (ET). We studied mirtazapine in a randomized, double‐blind, placebo‐controlled, crossover study of 17 ET patients. Patients were started with 15 mg per day of either mirtazapine or placebo for 1 week and the dose was escalated weekly until the targeted dose of 45 mg per day was achieved. This dose was maintained for 2 weeks. Tremor was assessed at baseline and after 14 days of 45 mg of mirtazapine or placebo. There was a minimum washout period of 14 days between the two arms of the study. Tremor assessments included global improvement, Fahn Tolosa Marin Tremor Rating Scale, Beck Depression Inventory and the Parkinson's Disease Questionnaire‐39. Patient global improvement ratings indicated that in the placebo condition 12 patients were unchanged and 1 patient was mildly improved. In the mirtazapine condition, 10 patients were unchanged, 2 were moderately improved and 1 was markedly improved. There was no significant improvement with mirtazapine or placebo compared to baseline as measured by the Tremor Rating Scale. Adverse effects were more common in the mirtazapine group and included drowsiness, confusion, dry mouth, weight gain, polyuria, itching, nausea, gait and balance problems, blurred vision, and bad taste. We conclude that the majority of the ET patients do not benefit from mirtazapine. Mirtazapine has significant adverse effects and should be used cautiously in ET patients. © 2003 Movement Disorder Society
Url:
DOI: 10.1002/mds.10371
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000245
- to stream Istex, to step Curation: 000245
- to stream Istex, to step Checkpoint: 002969
- to stream PubMed, to step Corpus: 003786
- to stream PubMed, to step Curation: 003786
- to stream PubMed, to step Checkpoint: 003731
- to stream Ncbi, to step Merge: 000A65
- to stream Ncbi, to step Curation: 000A65
- to stream Ncbi, to step Checkpoint: 000A65
- to stream Main, to step Merge: 005C62
- to stream PascalFrancis, to step Corpus: 002470
- to stream PascalFrancis, to step Curation: 000851
- to stream PascalFrancis, to step Checkpoint: 002406
- to stream Main, to step Merge: 005F52
- to stream Main, to step Curation: 004039
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mirtazapine in essential tremor: A double‐blind, placebo‐controlled pilot study</title><author><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name></author><author><name sortKey="Lyons, Kelly E" sort="Lyons, Kelly E" uniqKey="Lyons K" first="Kelly E." last="Lyons">Kelly E. Lyons</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B86C903B53C334411A48CDDCF02B35F72B79C6D6</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1002/mds.10371</idno><idno type="url">https://api.istex.fr/document/B86C903B53C334411A48CDDCF02B35F72B79C6D6/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000245</idno><idno type="wicri:Area/Istex/Curation">000245</idno><idno type="wicri:Area/Istex/Checkpoint">002969</idno><idno type="wicri:doubleKey">0885-3185:2003:Pahwa R:mirtazapine:in:essential</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:12722174</idno><idno type="wicri:Area/PubMed/Corpus">003786</idno><idno type="wicri:Area/PubMed/Curation">003786</idno><idno type="wicri:Area/PubMed/Checkpoint">003731</idno><idno type="wicri:Area/Ncbi/Merge">000A65</idno><idno type="wicri:Area/Ncbi/Curation">000A65</idno><idno type="wicri:Area/Ncbi/Checkpoint">000A65</idno><idno type="wicri:doubleKey">0885-3185:2003:Pahwa R:mirtazapine:in:essential</idno><idno type="wicri:Area/Main/Merge">005C62</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:03-0379961</idno><idno type="wicri:Area/PascalFrancis/Corpus">002470</idno><idno type="wicri:Area/PascalFrancis/Curation">000851</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002406</idno><idno type="wicri:doubleKey">0885-3185:2003:Pahwa R:mirtazapine:in:essential</idno><idno type="wicri:Area/Main/Merge">005F52</idno><idno type="wicri:Area/Main/Curation">004039</idno><idno type="wicri:Area/Main/Exploration">004039</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Mirtazapine in essential tremor: A double‐blind, placebo‐controlled pilot study</title><author><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</wicri:regionArea><placeName><region type="state">Kansas</region></placeName></affiliation></author><author><name sortKey="Lyons, Kelly E" sort="Lyons, Kelly E" uniqKey="Lyons K" first="Kelly E." last="Lyons">Kelly E. Lyons</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</wicri:regionArea><placeName><region type="state">Kansas</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2003-05">2003-05</date><biblScope unit="vol">18</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="584">584</biblScope><biblScope unit="page" to="587">587</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">B86C903B53C334411A48CDDCF02B35F72B79C6D6</idno><idno type="DOI">10.1002/mds.10371</idno><idno type="ArticleID">MDS10371</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antagonist</term><term>Antidepressive Agents, Tricyclic (administration & dosage)</term><term>Antidepressive Agents, Tricyclic (pharmacology)</term><term>Antidepressive Agents, Tricyclic (therapeutic use)</term><term>Chemotherapy</term><term>Cross-Over Studies</term><term>Double blind study</term><term>Double-Blind Method</term><term>Essential</term><term>Essential Tremor (diagnosis)</term><term>Essential Tremor (drug therapy)</term><term>Female</term><term>Human</term><term>Humans</term><term>Male</term><term>Mianserin (administration & dosage)</term><term>Mianserin (analogs & derivatives)</term><term>Mianserin (pharmacology)</term><term>Mianserin (therapeutic use)</term><term>Mirtazapine</term><term>Outcome Assessment (Health Care)</term><term>Placebo</term><term>Psychomotor Performance (drug effects)</term><term>Questionnaires</term><term>Severity of Illness Index</term><term>Treatment</term><term>Tremor</term><term>double‐blind</term><term>mirtazapine</term><term>placebo</term><term>tremor</term><term>α2-Adrenergic receptor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antidepressive Agents, Tricyclic</term><term>Mianserin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Mianserin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antidepressive Agents, Tricyclic</term><term>Mianserin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antidepressive Agents, Tricyclic</term><term>Mianserin</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Essential Tremor</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Psychomotor Performance</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Essential Tremor</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Cross-Over Studies</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Outcome Assessment (Health Care)</term><term>Questionnaires</term><term>Severity of Illness Index</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Antagoniste</term><term>Chimiothérapie</term><term>Essentiel</term><term>Etude double insu</term><term>Homme</term><term>Mirtazapine</term><term>Placebo</term><term>Récepteur α2-adrénergique</term><term>Traitement</term><term>Tremblement</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="fr">We sought to determine whether mirtazapine is safe and well‐tolerated as a treatment for essential tremor (ET). We studied mirtazapine in a randomized, double‐blind, placebo‐controlled, crossover study of 17 ET patients. Patients were started with 15 mg per day of either mirtazapine or placebo for 1 week and the dose was escalated weekly until the targeted dose of 45 mg per day was achieved. This dose was maintained for 2 weeks. Tremor was assessed at baseline and after 14 days of 45 mg of mirtazapine or placebo. There was a minimum washout period of 14 days between the two arms of the study. Tremor assessments included global improvement, Fahn Tolosa Marin Tremor Rating Scale, Beck Depression Inventory and the Parkinson's Disease Questionnaire‐39. Patient global improvement ratings indicated that in the placebo condition 12 patients were unchanged and 1 patient was mildly improved. In the mirtazapine condition, 10 patients were unchanged, 2 were moderately improved and 1 was markedly improved. There was no significant improvement with mirtazapine or placebo compared to baseline as measured by the Tremor Rating Scale. Adverse effects were more common in the mirtazapine group and included drowsiness, confusion, dry mouth, weight gain, polyuria, itching, nausea, gait and balance problems, blurred vision, and bad taste. We conclude that the majority of the ET patients do not benefit from mirtazapine. Mirtazapine has significant adverse effects and should be used cautiously in ET patients. © 2003 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Kansas</li></region></list><tree><country name="États-Unis"><region name="Kansas"><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name></region><name sortKey="Lyons, Kelly E" sort="Lyons, Kelly E" uniqKey="Lyons K" first="Kelly E." last="Lyons">Kelly E. Lyons</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004039 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004039 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:B86C903B53C334411A48CDDCF02B35F72B79C6D6
|texte= Mirtazapine in essential tremor: A double‐blind, placebo‐controlled pilot study
}}
| This area was generated with Dilib version V0.6.23. |  |